United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,652 shares of the biotechnology company's stock after selling 2,450 shares during the quarter. Martingale Asset Management L P owned about 0.08% of United Therapeutics worth $12,227,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics during the fourth quarter worth about $25,000. Millstone Evans Group LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth about $67,000. MassMutual Private Wealth & Trust FSB increased its position in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares during the period. Jones Financial Companies Lllp lifted its stake in United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $131,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other news, Director Raymond Dwek sold 4,000 shares of United Therapeutics stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00. Following the transaction, the director now directly owns 1,750 shares of the company's stock, valued at $497,962.50. The trade was a 69.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $956,195.85. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 77,500 shares of company stock worth $26,994,480. 11.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on UTHR shares. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.

United Therapeutics Price Performance

United Therapeutics stock traded up $0.70 during mid-day trading on Tuesday, hitting $285.01. 247,142 shares of the company were exchanged, compared to its average volume of 452,577. The company has a market capitalization of $12.80 billion, a P/E ratio of 12.52, a PEG ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 12-month low of $230.39 and a 12-month high of $417.82. The business's 50 day simple moving average is $321.83 and its two-hundred day simple moving average is $350.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business earned $4.36 earnings per share. Equities research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.